CONMED to exit gastroenterology lines; terminates Gore VIABIL agreement effective Jan 1, 2026

CONMED Corp

Gastroenterology product lines expected to generate $90M–$95M revenue in 2025 with ~45% gross margins.
Exit projected to cause EPS dilution of $0.45–$0.55 in 2026.
Consolidated gross margin expected to improve by ~80 bps after exit completion.
CONMED reaffirms full-year 2025 revenue guidance of $1.365B–$1.372B and adjusted EPS of $4.48–$4.53.
2026 guidance to be provided on Q4 2025 earnings call.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.